Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Businessweek Archives

Lilly Bows To The Ftc


In Business This Week

LILLY BOWS TO THE FTC

ELI LILLY'S $4 BILLION PURchase of a major drug benefits manager is likely to get a green light from trustbusters at the Federal Trade Commission after all--with strings. The company has agreed to FTC conditions meant to ensure that its acquisition of McKesson's PCS unit won't diminish competition: PCS will make its shopping list of drugs available to all drugmakers and will set up a "firewall" to prevent information on bids from rival drugmakers from flowing to Lilly, say sources close to the talks. Consumer advocates and trustbusters fear that drug benefits managers bought by pharmaceutical companies may favor their owners' products over those of rivals.EDITED BY KEITH H. HAMMONDS


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus